Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 14, 2012

Curetis Wins CE Mark for POC Diagnostic Platform, Pneumonia Test Cartridge

  • Molecular diagnostics firm Curetis announced the award of a CE mark for its Unyvero™ point of care diagnostic platform and the first disposable cartridge-based test for the system, P50 Pneumonia. The automated assay is designed to simultaneously test for 39 DNA targets from a range of pneumonia-causing bacteria and determine antibiotic resistance.

    The Unyvero system allows the fully automated DNA-based testing of any clinically relevant samples using the disposable cartridge format. The platform integrates pre-analytical and analytical steps into one cartridge that contains all the reagents required to complete analysis from sample to result, including sample conditioning/cell lysing, DNA purification and amplification, and detection. Results are generated within about 3 hours.

    Curetis says it is developing additional test cartridges for further applications including surgical site infections, blood stream infections, and tuberculosis. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »